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Background: Hepatocellular carcinoma (HCC) is one of the major causes of mortality. ABT-263 is a newly
synthesized, orally available Bcl-2/xL inhibitor that shows promising efficacy in HCC therapy. ABT-263 inhibits the
anti-apoptotic activity of Bcl-2 and Bcl-xL, but not Mcl-1. Previous reports have shown that ABT-263 upregulates
Mcl-1 in various cancer cells, which contributes to ABT-263 resistance in cancer therapy. However, the associated
mechanisms are not well known.
Methods: Western blot, RNAi and CCK-8 assays were used to investigate the relationship between Mcl-1 upregulation
and ABT-263 sensitivity in HCC cells. Real-time PCR and Western blot were used to detect Mcl-1 mRNA and protein
levels. Luciferase reporter assay and RNA synthesis inhibition assay were adopted to analyze the mechanism of Mcl-1
mRNA upregulation. Western blot and the inhibition assays for protein synthesis and proteasome were used to explore
the mechanisms of ABT-263-enhanced Mcl-1 protein stability. Trypan blue exclusion assay and flow cytometry were
used to examine cell death and apoptosis.
Results: ABT-263 upregulated Mcl-1 mRNA and protein levels in HCC cells, which contributes to ABT-263 resistance.
ABT-263 increased the mRNA level of Mcl-1 in HCC cells by enhancing the mRNA stability without influencing its
transcription. Furthermore, ABT-263 increased the protein stability of Mcl-1 through promoting ERK- and JNK-induced
phosphorylation of Mcl-1Thr163 and increasing the Akt-mediated inactivation of GSK-3β. Additionally, the inhibitors of
ERK, JNK or Akt sensitized ABT-263-induced apoptosis in HCC cells.
Conclusions: ABT-263 increases Mcl-1 stability at both mRNA and protein levels in HCC cells. Inhibition of ERK, JNK or
Akt activity sensitizes ABT-263-induced apoptosis. This study may provide novel insights into the Bcl-2-targeted cancer
therapeutics.
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Hepatocellular carcinoma (HCC) is one of the major
causes of mortality in developing countries, such as in
China, and its prevalence ranks the fifth of all tumors
with rapid increasing morbidity [1]. Currently, the effi-
cacy of traditional chemotherapy for HCC is often un-
satisfied [2]. Therefore, it is of great priority to develop
novel molecular targeted compounds. Recent studies* Correspondence: lianjiqin@sina.com; hefengtian06@aliyun.com
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unless otherwise stated.have shown that the inhibitors of Bcl-2 exhibit promis-
ing antitumor activity [3].
Bcl-2 family consists of three categories of proteins,
namely anti-apoptotic members, apoptosis executors and
pro-apoptotic BH3-only proteins. The balance of these
proteins contributes to survival and homeostasis of both
normal and tumor cells [4]. However, overexpression of
anti-apoptotic members Bcl-2 and Bcl-xL always happens
in tumors and indicates a poor prognosis [5-8]. Mean-
while, previous reports have also shown that the levels of
Bcl-2/xL are closely related to the pathological grade and
survival rate of HCC [9,10]. These studies imply thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HCC.
Some of the Bcl-2 inhibitors (that have been) developed
are a group of natural or synthesized compounds that tar-
get anti-apoptotic Bcl-2 family members especially Bcl-2
and Bcl-xL. ABT-263, also known as Navitoclax, is an or-
ally available analog of ABT-737, which can bind to Bcl-2
and Bcl-xL, but not Mcl-1 [4]. Several studies have shown
that ABT-263 exerts optimistic anti-tumor effects, espe-
cially in haematological malignancies and non-small cell
lung cancer [11]. Furthermore, ABT-263 is now in phaseII
clinical trials for several types of tumor with initial results
[12,13]. However, previous studies have shown that ABT-
263 upregulates Mcl-1 protein, which ultimately contrib-
utes to drug resistance [14,15].
Mcl-1 is an important anti-apoptotic protein that
mainly distributes in mitochondria and cytoplasm. Mcl-
1 exerts anti-apoptotic effects by interacting with pro-
apoptotic proteins such as Bim, Noxa, Bak and Bax.
Also, Mcl-1 may function by facilitating normal mito-
chondrial fusion, ATP production and respiration [16].
Therefore, Mcl-1 protein level is elaborately regulated inA B
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Figure 1 Upregulation of Mcl-1 is correlated with ABT-263 resistance
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blot. (D) Hep3B and Huh7 cells were transfected with control siRNA or Mcl
blot. (E) After transfected with Mcl-1 siRNA or control siRNA for 24 h, the H
36 h. Then the cell viability was analyzed by CCK-8 kit. Data were expressed
***: P < 0.0001).both normal and tumor cells [17], among which phos-
phorylation modification is a quite significant way. Others
reporting results and our previous data have shown that
ABT-263 upregulates Mcl-1 in HCC cells, which is the
crucial reason for ABT-263 resistance in cancer therapy.
However, the associated mechanisms are not well known
[14,18]. In the present study, we for the first time demon-
strated that ABT-263 upregulated Mcl-1 by enhancing the
stability of both Mcl-1 mRNA and protein, which con-
tributed to ABT-263 resistance in HCC cells. More-
over, inhibition of ERK, JNK or Akt activity sensitized
ABT-263-induced apoptosis. This study may provide novel
insights into the Bcl-2-targeted cancer therapeutics.
Results
Upregulation of Mcl-1 is correlated with ABT-263
resistance in HCC cells
Firstly, the expression levels of anti-apoptotic Bcl-2 fam-
ily members Bcl-2, Bcl-xL and Mcl-1 were analyzed with
Western blot in HCC cell lines PLC/PRF/5, Hep3B,
HepG2 and Huh7. As shown in Figure 1A, Mcl-1 was
highly expressed in all four HCC cell lines, but the levelsPLC Hep3B HepG2 Huh7
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pcDNA3.0) for 36 h, then the level of Mcl-1 was analyzed by Western
-1 siRNA for 36 h, then Mcl-1 protein level was analyzed by Western
CC cells were treated with 5 μM ABT-263 or vehicle DMSO for another
as the mean ± SD from three independent experiments. (*: P < 0.05;
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of Bcl-xL and Huh7 cells had almost no detectable Bcl-2.
Upon treatment with ABT-263, the level of Mcl-1 in-
creased dramatically in all HCC cell lines, but the levels of
Bcl-2 and Bcl-xL did not change significantly (Figure 1B).
Another Bcl-2 inhibitor AT-101 had similar effect on Mcl-
1 expression in HCC cells (Additional file 1: Figure S1).
To test whether the upregulation of Mcl-1 is affected by
Bcl-2 level, we knocked down Bcl-2 in Hep3B cells and
overexpressed it in Huh7 cells, respectively. As shown in
Figure 1C, the level of Mcl-1 remained unchanged upon
Bcl-2 downregulation or overexpression. Similar results
were also found when Bcl-xL was knocked down in Huh7
cells or overexpressed in Hep3B cells (date not shown).
These results indicated that ABT-263-induced Mcl-1 up-
regulation was independent of the levels of Bcl-2/xL in
HCC cells. Furthermore, consistent with previous reports
[19-21], Mcl-1 knockdown significantly enhanced the
cytotoxicity of ABT-263 in HCC cells (Figure 1D and E).
The above data indicated that the drug resistance of ABT-
263 was, at least partially, mediated by Mcl-1 upregula-
tion, which was not associated with the expression levels
of Bcl-2/xL in HCC cells.
ABT-263 upregulates Mcl-1 at both mRNA and protein
levels
To investigate the underlying mechanism of ABT-263-
induced Mcl-1 upregulation in HCC cells, both mRNA
and protein levels of Mcl-1 were analyzed after treat-
ment with ABT-263. Since PLC and Huh7 cell lines hadA
C
B
Figure 2 ABT-263 upregulates Mcl-1 at both mRNA and protein levels
for 24 h or with 5 μM ABT-263 for indicated times. Then RT-PCR was perfor
(B) HCC cells were treated with 5 μM ABT-263 or vehicle DMSO for 24 h, th
a control. Data were represented as mean ± SD from three independent e
(A), then the level of Mcl-1 was analyzed by Western blot, taking α-tubulina higher sensitivity to ABT-263 after Mcl-1 knockdown
(Figure 1E), they were chosen as target cells. As shown
in Figure 2, ABT-263 upregulated Mcl-1 at both mRNA
and protein levels in PLC and Huh7 cells revealed by
RT-PCR (Figure 2A), real-time PCR (Figure 2B) and
Western blot (Figure 2C).
ABT-263 increases the mRNA stability of Mcl-1
To figure out the mechanisms of ABT-263-mediated
Mcl-1 mRNA upregulation, the promoter region of Mcl-
1 gene (−3009 to +251, named M1) was cloned into re-
porter vector pGL3-basic, and the resulting plasmid was
named as pLucM1 (Figure 3A). Meanwhile, the pro-
moter region (−607 to +251, named M2) containing the
binding sites for several predicted transcriptional factors
was also cloned into pGL3-basic, and the resulting plas-
mid was named as pLucM2 (Figure 3A). Then PLC and
Huh7 cells were separately transfected with pLucM1 and
pLucM2 and followed by the treatment with ABT-263.
As shown in Figure 3B, ABT-263 didn’t affect the activ-
ity of Mcl-1 promoter in HCC cells, neither in pLucM1
nor in pLucM2. Subsequently, PLC and Huh7 cells were
treated with transcription inhibitor actinomycin D (Act
D) in the presence or absence of ABT-263. As shown in
Figure 3C, ABT-263 co-treatment significantly enhanced
the mRNA stability of Mcl-1 compared to Act D treat-
ment alone (p < 0.05). These results indicated that ABT-
263 upregulated Mcl-1 mRNA level via increasing the
mRNA stability instead of activating its transcription in
HCC cells.. (A) PLC and Huh7 cells were treated with various doses of ABT-263
med to detect the level of Mcl-1 mRNA, taking β-actin as a control.
en qPCR was performed to quantitate Mcl-1 mRNA, taking β-actin as
xperiments. (*: P < 0.05). (C) HCC cells were treated as described in
as a loading control.
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Figure 3 ABT-263 increases the mRNA stability of Mcl-1. (A) Schematic representation of Mcl-1 promoter region containing several transcription
factor binding sites. Two fragments (−3009 to +251 and −607 to +251) were separately amplified from genomic DNA of HepG2 cells and inserted into
pGL3-basic vector, and the resulting plasmids were named as pLucM1 and pLucM2 respectively. (B) After co-transfected with pLucM1 or pLucM2 and
pCMV-β-gal plasmid for 12 h, the HCC cells were treated with 5 μM ABT-263 or vehicle DMSO for another 24 h. Then the luciferase assay was
performed. Data were expressed as mean ± SD from three independent experiments. (C) HCC cells were treated with 10 μg/ml actinomycin D
(Act D) in the presence or absence of 5 μM ABT-263 for indicated times, then the level of Mcl-1 mRNA was quantified by qPCR, taking β-actin as
a control. Data were represented as mean ± SD from three independent experiments. (*: P < 0.05).
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To assess whether the increase of Mcl-1 protein solely
results from the upregulation of Mcl-1 mRNA, the HCC
cells were treated with translation inhibitor cyclohexi-
mide (CHX). As shown in Figure 4A and B, the level of
Mcl-1 protein decreased dramatically after treatment
with CHX alone, and the half-life of Mcl-1 protein was
30 min. Co-treatment with ABT-263 and CHX mark-
edly attenuated the degradation of Mcl-1 protein, and
the half-life of Mcl-1 protein reached to more than 4 h.
These results indicated that ABT-263 enhanced Mcl-1
protein stabilization in HCC cells. Meanwhile, ABT-263
could not further upregulate Mcl-1 protein level after
proteasome was inhibited by MG132, suggesting that
ABT-263 might upregulate Mcl-1 protein level by de-
creasing proteasome-mediated degradation (Figure 4C).
As to whether ABT-263 affected the ubiquitination-
mediated Mcl-1 degradation, the role of deubiquitinase
USP9X (ubiquitin-specific peptidase 9, X-linked) was in-
vestigated. As shown in Figure 4D and E, knockdown of
USP9X didn’t affect ABT-263-mediated Mcl-1 accumu-
lation, indicating that USP9X-mediated deubiquitina-
tion doesn’t contribute to ABT-263-enhanced Mcl-1
stability.Activation of ERK and JNK involves in ABT-263-induced
stabilization of Mcl-1 protein
It is known that there is a unique PEST region in Mcl-1
protein and the phosphorylation of this region is closely
associated with Mcl-1 protein stability [22], so we ana-
lyzed the activity of several kinases which directly phos-
phorylate Mcl-1, including extracellular regulated kinase
(ERK) and c-Jun terminal kinase (JNK). Meanwhile, phos-
phorylation of mammalian target of rapamycin (mTOR)
was also detected upon ABT-263 treatment since its acti-
vation through phosphorylation can regulate the trans-
lational process of Mcl-1 protein [23]. As shown in
Figure 5A, ERK and JNK were activated while mTOR was
repressed after treatment with ABT-263. To further clarify
the role of these kinases in ABT-263-enhanced Mcl-1 pro-
tein stabilization, their inhibitors were used. ERK inhibitor
U0126 and JNK inhibitor SP600125, but not mTOR in-
hibitor rapamycin, markedly attenuated ABT-263-caused
Mcl-1 upregulation (Figure 5B). Moreover, ERK and JNK
inhibitors significantly increased ABT-263-induced apop-
tosis in PLC and Huh7 cells revealed by annexin V-FITC/
PI staining flow cytometry analysis (Figure 5C), trypan
blue exclusion assay (Figure 5D) and Western blot for en-
hanced PARP cleavage (Figure 5E and F). These results
A
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Figure 4 ABT-263 increases the protein stability of Mcl-1. (A, B) After pretreated with 5 μM ABT-263 or vehicle DMSO for 12 h, PLC cells were
treated with 10 μM CHX for indicated times. The level of Mcl-1 protein was detected by Western blot taking α-tubulin as a loading control (A), and the
relative level of Mcl-1 protein was calculated (B) as follows: (1) quantifying the mean ratio of Mcl-1/α-tubulin for each sample according to the Western blot
results from triplicate assays and (2) calculating the fold induction of Mcl-1 by normalizing the mean Mcl-1/α-tubulin ratio of the tested sample to that of
corresponding control (CHX 0 min). Data were expressed as mean ± SD from three independent experiments. (C) After pretreated with 10 μM proteasome
inhibitor MG132 for 2 h, the HCC cells were incubated with 5 μM ABT-263 or vehicle DMSO for 6 h. Then the level of Mcl-1 protein was detected by
Western blot. (D) HCC cells were transfected with USP9X-specific siRNA or control siRNA for 36 h, then the mRNA level of USP9X was analyzed by
RT-PCR. (E) After transfected with USP9X-specific siRNA or control siRNA for 24 h, the HCC cells were treated with 5 μM ABT-263 or vehicle DMSO
for another 18 h. Then the level of Mcl-1 protein was analyzed by Western blot.
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involved in ABT-263-mediated Mcl-1 protein stabilization
and drug resistance.
ABT-263 enhances ERK- and JNK-mediated Mcl-1Thr163
phosphorylation
To further investigate the concrete mechanisms of ERK-
and JNK-mediated Mcl-1 stabilization, the phosphoryl-
ation status of Mcl-1Thr163 was analyzed. As shown in
Figure 5E and F, inhibition of ERK or JNK significantly
attenuated ABT-263-induced Mcl-1Thr163 phosphoryl-
ation and Mcl-1 accumulation, suggesting that the phos-
phorylation of Mcl-1Thr163 may contribute to ERK- and
JNK-mediated Mcl-1 stabilization upon ABT-263 treat-
ment in HCC cells.
Akt-mediated GSK-3β inactivation also involves in
ABT-263-induced Mcl-1 stabilization
Since Serine159 is also closely related with Mcl-1 stability
and this site is mainly phosphorylated by GSK-3β [24],
we tested whether GSK-3β involves in ABT-263-induced
Mcl-1 stabilization in HCC cells. As shown in Figure 6A,ABT-263 increased the phosphorylation of GSK-3β, but
no effect on total GSK-3β. Meanwhile, ABT-263 en-
hanced the phosphorylation of Akt, an upstream signal
molecule of GSK-3β. Suppression of Akt by its inhibitor
BEZ-235 dramatically attenuated ABT-263-mediated
GSK-3β phosphorylation, Mcl-1 upregulation and apop-
tosis resistance (Figure 6B). Subsequently, we checked
whether the phosphorylation of GSK-3β is also affected
by ERK, another upstream regulator of GSK-3β. As
shown in Figure 6C, inhibition of ERK with U0126 had
no effect on ABT-263-triggered GSK-3β phosphoryl-
ation, indicating that GSK-3β activity was not regulated
by ERK in this process. Furthermore, Akt inhibitor also
increased the cytotoxicity of ABT-263 in HCC cells
(Figure 6D). These results indicated that Akt-mediated
GSK-3β inactivation also involves in ABT-263-induced
Mcl-1 stabilization, possibly through regulating the
phosphorylation of Mcl-1Ser159.
Discussion
In the present study, we demonstrated that ABT-263 up-
regulated Mcl-1 by increasing the stability of Mcl-1
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Figure 5 ABT-263 enhances ERK- and JNK-mediated Mcl-1Thr163 phosphorylation and protein stabilization. (A) HCC cells were treated
with 5 μM ABT-263 for 18 h, and then the phosphorylation of ERK1/2, JNK and mTOR were detected by Western blot, taking α-tubulin as a loading
control. (B) After pretreated with 10 μM ERK1/2 inhibitor U0126, 10 μM JNK inhibitor SP600125 (SP), or 2 μM mTOR inhibitor rapamycin for 2 h, the
HCC cells were treated with 5 μM ABT-263 for another 18 h. Then the level of Mcl-1 protein was analyzed by Western blot. (C) After pretreated with
10 μM U0126 or 10 μM SP600125 for 2 h, the HCC cells were treated with 5 μM ABT-263 for 24 h, then the cells were stained with annexin V-FITC/PI
and analyzed by flow cytometry. (D) After pretreated with 10 μM U0126 or 10 μM SP600125 for 2 h, the HCC cells were treated with 5 μM ABT-263 for
another 24 h. Then the total cell death was calculated by trypan blue exclusion assay. Data were expressed as mean ± SD from three independent
experiments. (*: P < 0.05, ***: P < 0.0001). (E, F) After pretreated with 10 μM U0126 or 10 μM SP600125 for 2 h, the HCC cells were treated with 5 μM
ABT-263 for another 18 h. Then PARP and cleaved PARP, p-ERK, p-JNK, Mcl-1 and p-Mcl-1(Thr163) were analyzed by Western blot.
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ing model (Figure 7), ABT-263 increased Mcl-1 mRNA
level by augmenting its stability instead of transcrip-
tional activation. Meanwhile, ABT-263 enhanced Mcl-1
protein stability by regulating the phosphorylation status
of Mcl-1. ERK- and JNK-mediated Mcl-1Thr163 phos-
phorylation contributed to ABT-263-induced Mcl-1 pro-
tein stability. Akt-mediated GSK-3β inactivation also
played important role in preventing Mcl-1 protein deg-
radation in the presence of ABT-263.
ABT-263, a newly-developed, oral-tolerant Bcl-2/xL in-
hibitor, has shown promising anti-tumor efficacy in non-
small cell lung cancer and acute lymphoblastic leukemiaas single agent both in vitro and in vivo [25]. Meanwhile,
ABT-263 can markedly sensitize several clinical drugs in
cancer therapy [26,27]. However, a recent study has dem-
onstrated that HCC cells are relatively resistant to ABT-
737 (analog of ABT-263) compared to leukemia and lung
carcinomas [28]. Furthermore, it has been indicated that
ABT-737-induced Mcl-1 upregulation contributes to this
resistance [14]. Consistent with ABT-737, our results
showed that both ABT-263 and another Bcl-2 inhibitor
AT-101 upregulated Mcl-1 in HCC cells, which at last re-
sulted in drug resistance. So it is important to clarify the
associated mechanisms of ABT-263-induced Mcl-1 upreg-
ulation in HCC cells.
A B
C D
Figure 6 Akt-mediated GSK-3β inactivation also involves in ABT-263-induced stabilization of Mcl-1 protein. (A) HCC cells were treated
with 5 μM ABT-263 for 18 h, then p-Akt (Ser473), p-GSK3β (Ser9) and total GSK3β (t-GSK3β) were detected by Western blot, taking α-tubulin as a
loading control. (B) After pretreated with 150nM PI3K/mTOR dual inhibitor NVP-BEZ235 for 2 h, the HCC cells were treated with 5 μM ABT-263 for
18 h. Then p-GSK3β (Ser9) and t-GSK3β, Mcl-1, PARP and cleaved PARP were analyzed by Western blot. (C) After pretreated with 10 μM ERK1/2
inhibitor U0126 for 2 h, the HCC cells were treated with 5 μM ABT-263 for 18 h. Then p-GSK3β (Ser9) and t-GSK3β were detected by Western blot.
(D) After pretreated with 150nM NVP-BEZ235 for 2 h, the HCC cells were treated with 5 μM ABT-263 for another 24 h. Then the total cell death
was analyzed by trypan blue exclusion assay. Data were expressed as mean ± SD from three independent experiments. (**: P < 0.01, ***: P < 0.0001).
Figure 7 Schematic illustration for the action mechanisms of ABT-263-induced Mcl-1 upregulation in HCC cells. ABT-263 increases Mcl-1
mRNA level by augmenting its stability instead of transcriptional activation. Meanwhile, ABT-263 enhances Mcl-1 protein stability by regulating
the phosphorylation status of Mcl-1. ERK- and JNK-mediated Mcl-1Thr163 phosphorylation contribute to ABT-263-induced Mcl-1 protein stability.
Akt-mediated GSK-3β inactivation also plays important role in preventing Mcl-1 protein degradation in the presence of ABT-263. By increasing
Mcl-1 stability at both mRNA and protein levels, ABT-263 induces Mcl-1 upregulation.
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protein, which is now becoming a quite important target
for cancer therapy [29]. Characteristically, it has a short
half-life and is elaborately regulated at different levels
[17]. We found that ABT-263 increased Mcl-1 mRNA
level in HCC cells. It is also reported that Mcl-1 can be
regulated by several transcription factors, including
STAT3 [30], ATF4 [31], CREB [32] and HIF-1 [33].
However, the luciferase assay results in this study dem-
onstrated that ABT-263 did not increase the transcrip-
tional activity of Mcl-1 promoter, indicating that these
transcription factors may not play dominated roles in
this process. Furthermore, we demonstrated that ABT-
263 enhanced Mcl-1 mRNA stability in HCC cells. It is
known that RNA stability is affected by various factors
such as RNases and RNA binding proteins, but just only
one RNA binding protein CUGBP2 has been reported to
play a role in Mcl-1 mRNA stabilization [34]. Therefore,
it is unclear at present whether ABT-263-enhanced Mcl-
1 mRNA stability is associated with CUGBP2, which is
interesting and needs further studies.
Besides mRNA level, protein stability also plays im-
portant role in the upregulation of Mcl-1 protein. It is
known that the phosphorylation of Mcl-1 is closely asso-
ciated with Mcl-1 protein stabilization [22]. Serine159
and Threonine163 are two important phosphorylation
sites in Mcl-1 PEST region to determine the fate of Mcl-
1 degradation. Mcl-1 can be phosphorylated by ERK at
its Thr163 site, which prolongs the half life of this protein
[35]. ERK mediated-phosphorylation at Thr163 repre-
sents an important resistant mechanism in leukemia
cells [15] and the inhibition of MEK/ERK sensitizes the
anti-tumor effect of ABT-737 [36]. Consistent with these
reports, our study showed that ERK-mediated Thr163
phosphorylation of Mcl-1 contributed to ABT-263 resist-
ance in HCC cells. JNK, another important member of
MAPK family, can phosphorylate Mcl-1 at several sites,
but the effect of JNK on Mcl-1 is varied [22]. JNK-
mediated Thr163 phosphorylation may lead to enhanced
Mcl-1 degradation [37] or increased Mcl-1 stabilization
[38]. Our data demonstrated that ABT-263 increased JNK-
mediated Mcl-1Thr163 phosphorylation, which enhanced
Mcl-1 protein stability in HCC cells. Furthermore, both
ERK and JNK inhibitors sensitized ABT-263-induced
apoptosis and cell death by downregulating Mcl-1 in
HCC cells, which may be novel ways to sensitize ABT-263
in HCC therapy.
GSK-3β plays an important role in glucose metabolism
in mammalian cells. After being phosphorylated at
Serine9, GSK-3β loses its activity. It is known that Mcl-1
can be phosphorylated by GSK-3β at Ser159 site, which
decreases Mcl-1 stability [24]. A recent study has shown
that ABT-263 enhances the anti-tumor effect of PI3K in-
hibitor in GSK3-dependent manner in human myeloidleukemia cells, but the detailed mechanisms are still not
clear [39]. Our study demonstrated that ABT-263 pro-
moted GSK-3β inactivation and Mcl-1 stability via Akt
pathway, indicating that inhibition of Akt may be a good
strategy to sensitize ABT-263 in HCC treatment.
It is well known that Bcl-2/xL are involved in regulat-
ing the homeostasis of apoptosis, autophagy and oxida-
tive stress in the cells [40], which are associated with
ERK, JNK and Akt pathways. ABT-263 is known as a
specific inhibitor of Bcl-2/xL, so the mechanisms by
which ABT-263 activates ERK, JNK and Akt may be
complicated. Our previous data have shown that Bcl-2
inhibitor apogossypolone can induce reactive oxygen
species (ROS) in HCC cells, which results in the activa-
tion of multiple vital signaling pathways including ERK,
JNK and Akt pathways [41]. In the present study, we
demonstrated that ABT-263 could induce the phosphory-
lations of ERK, JNK and Akt, which were markedly atten-
uated by the widely used antioxidant N-acetyl-cysteine
(Additional file 1: Figure S2), suggesting that ABT-263
may activates ERK, JNK and Akt via , at least partially,
inducing ROS production.
Conclusions
In conclusion, our study demonstrates that ABT-263
upregulates Mcl-1 through increasing its mRNA and
protein stability, which contributes to the resistance of
ABT-263 in HCC cells. Inhibition of ERK-, JNK- or Akt-
mediated Mcl-1 stability may confer Bcl-2 inhibitor better
anti-tumor effect in HCC cells. Our results may provide
more details to Bcl-2-targeted therapeutics and give in-
sights into the future clinical trials of Bcl-2 inhibitors
in HCC therapy.
Materials and methods
Materials
The cell culture reagents were purchased from Hyclone
(Waltham, MA, USA). ABT-263, cycloheximide, SP600125,
rapamycin, NVP-BEZ235 and N-acetyl-cysteine were pur-
chased from Sigma-Aldrich (Louis, MO, USA). U0126,
Act D, MG132, the antibody against α-tubulin, BCA pro-
tein assay kit and RIPA lysis buffer were purchased from
Beyotime Biotechnology (Shanghai, China). AnnexinV-
FITC/propidium iodide (PI) apoptosis detection kit was
purchased from BD bioscience (BD, NJ, USA). Cell Count-
ing Kit-8 (CCK-8) was from Dojindo (Shanghai, China).
Trizol agent, M-MLV transcriptase and Lipofectamin 2000
were from Invitrogen (Carlsbad, CA, USA). SYBR qPCR
master mix, PrimeSTAR HS DNA polymerase, restriction
endonuclease NheIand HindIII were from TAKARA (Shiga,
Japan). pGL3-basic vector, pCMV-β-gal plasmid, lucifer-
ase assay and β-gal assay systems were from Promega
(Madison, WI, USA). Antibodies of Mcl-1 and Bcl-2
were purchased from Santa Cruz Biotechnology (Santa
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PARP, phosphorylated ERK1/2 (p-ERK1/2, Thr202/Tyr204),
total-ERK, p-JNK(Thr183/Tyr185), p-mTOR(Ser2448),
p-Mcl-1(Thr163), p-Akt(Ser473), p-GSK-3β(Ser9) and
total-GSK-3β were from Cell Signaling Technology
(Boston, MA, USA). HRP-conjugated goat anti-rabbit
and anti-mouse IgG were purchased from Zhongshan
Company (Beijing, China). siRNAs to Bcl-2, Bcl-xL,
USP9X and control siRNAs were from Dharmacon
(Lafayette, CO, USA). pcDNA3-Bcl-2 and pcDNA3-Bcl-
xL expression plasmids were kindly gifts from University
of Michigan( pcDNA3.0 was used as negative control).
Cell culture
Human HCC cell lines PLC/PRF/5, HepG2, Huh7 and
Hep3B were purchased from American Type Culture
Collection (ATCC), and cultured in high-glucose DMEM
(Dulbecco’s modified Eagle’s medium) with 10% FBS
(fetal bovine serum), streptomycin (100 μg/mL) and
penicillin(100 U/mL). These cell lines were originally
tested by ATCC and passaged less than 6 months in the
lab.
Quantitative polymerase chain reaction (qPCR)
After treatment, the cells were lysed and total RNA was
extracted with Trizol agent as described [42], and first-
strand cDNA was synthesized using M-MLV transcript-
ase. qPCR was performed to detect the level of Mcl-1
mRNA using SYBR qPCR master mix in a 25 μl volume
according to the manufacturer’s instruction. The sequences
of different primers were as follows: Mcl-1: forward primer
5′-AAAGCCTGTCTGCCAAAT-3′ and reverse primer 5′-
CCTATAAACCCACCACTC-3′; USP9X: forward primer
5′-CCTGCTGGTGCACCTCTGGC-3′ and reverse primer
5′-AGGCCGGTGTCCCATGCAA-3′; β-actin: forward
primer 5′-ATCGTGCGTGACATTAAGGAGAAG-3′
and reverse primer 5′-AGGAAGGAAGGCTGGAAGA
GTG-3′.
Western blot
After treatment, the cells were harvested and whole-cell
lysates were prepared. The protein concentrations were
measured by BCA protein assay kit. Subsequently, Western
blot analysis was performed as described [41].
Transfection of siRNA and Bcl-2/xL expression plasmid
The HCC cells were separately transfected with siR-
NAs to Bcl-2 (or Bcl-xL or USP9X) and control siRNA
using Lipofectamine 2000 according to the manufac-
turer’s instruction. Similarly, the expression plasmid
pcDNA3-Bcl-2 or pcDNA3-Bcl-xL was transfected
into the corresponding HCC cells, taking pcDNA3.0 as
negative control.Cell viability assay
Cell viability assay was performed by using Cell Count-
ing Kit-8 (CCK-8). Briefly, cells were seeded in triplicate
in 96-well plates and given different treatments for indi-
cated time, then the OD value at 450 nm was detected
according to the manufacturer’s instruction.
Plasmid construction
Human Mcl-1 promoter regions −3009 to +251(M1)
and −607 to +251(M2) were amplified by PCR using
PrimeSTAR HS DNA polymerase taking genomic DNA
of HepG2 cells as template. The two PCR fragments
were separately inserted into pGL3-basic vector after di-
gestion with restriction endonucleases NheI and HindIII,
and the resulting plasmids were named as pLucM1 and
pLucM2, respectively.
Luciferase reporter assay
PLC and Huh7 cells were seeded in 48-well plates and
were co-transfected with pLucM1 or pLucM2 and moni-
tor plasmid pCMV-β-gal using Lipofectamin 2000 ac-
cording to the manufacturer’s protocol. After 36 h, the
cells were lysed, and luciferase activity and β-gal activity
were separately detected using Promega luciferase and
β-gal assay systems according to the manufacturer’s proto-
cols. The luciferase activity was normalized against β-gal
activity. The transfection experiments were performed at
least three times in triplicate. Data were represented as
fold induction by normalizing the luciferase activity of the
tested sample to that of the corresponding control sample.
Trypan blue exclusion assay
The trypan blue exclusion assay was performed as de-
scribed [41]. The total death rate (%) = numbers of
dead cells/(numbers of living cells + numbers of dead
cells) × 100.
Flow cytometry
After treatment, the HCC cells were harvested and incu-
bated with annexin V-FITC and PI according to the man-
ufacturer’s instructions. Then the apoptosis were analyzed
by a flow cytometer.
Statistic analysis
The data were expressed as Mean ± SD. Two-way t-test
and ANOVA were used to analyze the variance. P < 0.05
was defined as statistically significant.
Additional file
Additional file 1: Figure S1. Bcl-2 inhibitor AT-101 upregulates Mcl-1 in
four HCC cell lines. HCC cells were treated with 10 μM AT-101 or vehicle
DMSO for 18 h, then the protein level of Mcl-1 was analyzed by Western
blot, taking α-tubulin as a loading control. Figure S2. N-acetyl-L-cysteine
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phophorylation of ERK, JNK and Akt. After pretreated with 10 mM
N-acetyl-cysteine (NAC) for 2 h, the HCC cells were treated with 5 μM
ABT-263 or vehicle DMSO for another 18 h. Then Mcl-1, p-ERK, p-JNK
and p-Akt were detected by Western blot, taking α-tubulin as a
loading control.
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